Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2025-12-25 @ 3:28 AM
NCT ID:
NCT00215605
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective
* Eastern Cooperative Oncology Group (ECOG) performance status \</= 2
* Life expectancy greater than 3 months
* Adequate organ and marrow function
* Written informed consent
* Use of acceptable methods of contraception during the course of the study and for 3 months after completion of study
* In the MTD expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST
Exclusion Criteria:
* Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first scheduled dose of XL184
* Administration of an investigational drug within 30 days of the first dose of XL184
* Subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment
* Known brain metastases
* Uncontrolled intercurrent illness
* Pregnancy or breastfeeding
* Known HIV positive
* Known allergy or hypersensitivity to any of the components of the XL184 formulation
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00215605
Study Brief:
Protocol Section:
NCT00215605